Polypeptide antibiotics are a chemically diverse class of anti-infective and antitumor antibiotics containing non-protein polypeptide chains. Examples of this class include actinomycin, bacitracin, colistin, and polymyxin B.
They feature 'polypeptide' rings, i.e. complex amino-acid polymers in a ring-like structure.
The first examples were 'polymyxins' discovered in 1947 from bacterial cultures. Some are now produced from fungi. It has since been discovered that polypeptide antibiotics appear to be produced by all living organisms; largely by bacteria and generally function as natural host defence.
Some have toxic side effects and tend to be used as last-resort treatments, or for very specific uses where they have been found to out-perform other types.
The mecahnism of action of this entire group of antibiotics is currently unknown.
Despite thousands of articles about hundreds of these polypeptide antibiotics over several decades, basic questions about their mechanism of action remain unanswered. Most investigators have concluded that they act solely by permeabilizing the bacterial cell membrane. Although strong evidence for another mechanism of action has not yet emerged, this conclusion may not represent the whole story because polypeptide antibiotics clearly have other significant effects on bacteria
Source Biophysical Journal 94(5): 1549–1550.
Ideas for new topics, and suggested additions / corrections for old ones, are always welcome.
If you have skills or interests in a particular field, and have suggestions for Wikenigma, get in touch !
Or, if you'd like to become a regular contributor . . . request a login password. Registered users can edit the entire content of the site, and also create new pages.
( The 'Notes for contributors' section in the main menu has further information and guidelines etc.)